Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28183325 | 0.92 | HCAR3 (0.86) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL2252228 | 0.90 | MAPT (0.82) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL31425079 | 0.90 | HCAR3 (0.81) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL2552519 | 0.88 | HCAR3 (0.79) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL6044291 | 0.87 | HCAR3 (0.77) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| Methyl Alcohol SCHEMBL28201441 | 0.87 | HCAR3 (0.76) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL1964842 | 0.85 | MAPT (1.00) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL2688335 | 0.85 | HCAR3 (1.00) | HCAR3MAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL581227 | 0.85 | HCAR3 (0.73) | HCAR3MAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL5591695 | 0.84 | HCAR3 (0.72) | HCAR3MAPTALDH1A1PTGER4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-04 | — | — | US | disclosed |
| CN-105814038-B | Benzimidazole derivatives as EP4 ligands | 拜耳医药股份公司 | 2018-12-04 | — | — | CN | disclosed |
| CN-104854098-B | Benzimidazole derivatives as EP4 antagonists | 拜耳医药股份公司 | 2018-01-09 | — | — | CN | disclosed |
| EP-3083603-B1 | BENZIMIDAZOLYL DERIVATIVES AS EP4 LIGANDS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-3083603-B1 | BENZIMIDAZOLYL DERIVATIVES AS EP4 LIGANDS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| EP-2928884-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma AG (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| CN-105814038-A | Benzimidazole derivatives as EP4 ligands | 拜耳医药股份公司 | 2016-07-27 | — | — | CN | disclosed |
| EP-2928884-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-14 | — | — | EP | disclosed |
| CN-104854098-A | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma AG | 2015-08-19 | — | — | CN | disclosed |
| WO-2015091475-A1 | BENZIMIDAZOLE DERIVATIVES AS EP4-LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091475-A1 | BENZIMIDAZOLE DERIVATIVES AS EP4-LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014086739-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | PTGER4, PTGER1, PTGER2 | HCAR3 893/4885MAPT 4657/4885ALDH1A1 560/4885 |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, EPB41 | HCAR3 1038/4885MAPT 4631/4885ALDH1A1 511/4885 |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885MAPT 3284/4885ALDH1A1 607/4885 |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, PTGER2 | HCAR3 841/4885MAPT 4684/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.